To elucidate the genetic architecture of familial schizophrenia we combine linkage analysis with studies of fine-level chromosomal variation in families recruited from the Afrikaner population in South Africa. We demonstrate that individually rare inherited copy number variants (CNVs) are more frequent in cases with familial schizophrenia as compared to unaffected controls and affect almost exclusively genic regions. Interestingly, we find that while the prevalence of rare structural variants is similar in familial and sporadic cases, the type of variants is markedly different. In addition, using a high-density linkage scan with a panel of nearly 2,000 markers, we identify a region on chromosome 13q34 that shows genome-wide significant linkage to schizophrenia and show that in the families not linked to this locus, there is evidence for linkage to chromosome 1p36. No causative CNVs were identified in either locus. Overall, our results from approaches designed to detect risk variants with relatively low frequency and high penetrance in a well-defined and relatively homogeneous population, provide strong empirical evidence supporting the notion that multiple genetic variants, including individually rare ones, that affect many different genes contribute to the genetic risk of familial schizophrenia. They also highlight differences in the genetic architecture of the familial and sporadic forms of the disease.
S chizophrenia (SCZ) is a chronic, psychiatric disorder that has an estimated worldwide prevalence of Ϸ1%. The genetic architecture of the disease remains largely unknown. The strongest predictor of SCZ is having an affected first-degree relative (1) . In addition to the familial forms, nonfamilial (sporadic) forms of the disease also exist (1, 2) . The exact proportion of each form is largely unknown, but it is thought that at least 60% of cases are sporadic (3, 4) . Genome-wide linkage scans have been conducted to identify loci harboring rare mutations/ variants that increase susceptibility to familial SCZ. Loci have been identified on almost every chromosome, but only a few regions have been replicated across studies. One such region is near the telomere of chromosome 13q (5) (6) (7) (8) (9) (10) (11) (12) . Across studies the region of peak linkage is broad, from 13q12 to 13q34. This region has also been linked to bipolar disorder (13) . In addition to linkage studies, a number of earlier (14) as well as more recent studies (15) (16) (17) (18) have provided strong evidence supporting the importance of rare structural mutations/variants in SCZ vulnerability. Rare inherited structural lesions, in particular, are expected to be prominent in familial SCZ, but their full contribution to transmitted liability in familial SCZ cases has not been examined so far in a systematic manner (19) .
To understand the genetic architecture of familial SCZ and the pattern of transmission of rare risk alleles in affected families, we combine high-resolution linkage analysis with studies of fine-level chromosomal variation in families recruited from the Afrikaner population in South Africa, a genetically and environmentally homogeneous population who have descended from mostly Dutch immigrants who settled in South Africa beginning in 1652 (20) . In addition to the genetic homogeneity, the Afrikaners are valuable for genetic studies because they present a close-knit family structure and offer the potential to perform detailed genealogical analysis, which affords reliable discrimination of familial and nonfamilial forms of the disease and facilitates family-based genetic studies. Here, using approaches designed to detect risk variants with relatively lowfrequency and high penetrance, we provide strong empirical evidence supporting the notion that multiple genetic variants, including individually rare ones that affect many different genes, contribute to the genetic risk of familial SCZ.
Results

Patient Cohorts.
We performed a genome-wide survey of rare inherited copy number variants (CNVs) in a total of 182 individuals, consisting of 48 probands with familial SCZ [positive disease history in a first-degree (n ϭ 33) or second-degree (n ϭ 15) relative; Fig. S1 ] and both of their biological parents, as well as all additional affected relatives that were available for genotyping. Of the 48 probands, 40 are diagnosed as affected in the narrow category and eight in the broad category (see Methods). The familial cases cohort was compared to a control cohort (n ϭ 159 triad families) as well as to a cohort enriched in sporadic cases (n ϭ 152 triad families), defined as cases with negative family history of SCZ in a first-or second-degree relatives, also recruited from the Afrikaner community as previously described (15) . In that respect, it should be noted that there were no significant differences in the average number of first-or seconddegree relatives among families with and without family history. Specifically, in the 48 families with positive family history of SCZ in first-or second-degree relatives reported here, the average proband sibship was comprised of 3.4, the average maternal sibship of 4.3, and the average paternal sibship of 4.2 individuals. In the cohort enriched in sporadic cases (15) , these numbers are 3.3, 4.3, and 4.6, respectively. Negative or positive family history or availability of additional affecteds was not a screening criterion (see Methods).
For our linkage studies, we genotyped 479 subjects from 130 families. Sixty-nine families are informative. In these, 112 indi-viduals are diagnosed as affected in the narrow category, and 128 individuals are classified as broadly affected. In the 54 informative families with at least two affected members, there are 60 and 79 affected relative pairs for the narrow and broad affection categories, respectively (Table S1 ); this is 43% more affected relative pairs than in our previous, 9-cM, linkage study (12) . A subset of the families (67%) used in the CNV studies (n ϭ 32) was also included in the linkage scan. The appropriate Institutional Review Boards and Ethics Committees at University of Pretoria and Columbia University have approved all procedures for this study.
Genome-Wide Survey of Rare Inherited CNVs. We surveyed single nucleotide polymorphisms (SNPs) and CNVs using the Affymetrix Genome-Wide Human SNP 5.0 arrays and used intensity and genotype data from both SNP and CN probes to identify autosomal deletions and duplications as described previously (15) . The estimated rare inherited mutation rate was compared to the collective rate of inherited CNVs among sporadic cases and unaffected individuals from the same population (15) . Rare inherited CNVs detected in familial cases and their parents were considered only if they involved at least 10 consecutive probe sets (average resolution of Ϸ30 kb) and did not show Ն50% overlap with a CNV detected in any parental chromosome (other than those of the biological parents) in the familial, sporadic, or control cohorts (n ϭ 1,432 chromosomes). Using these criteria, we identified 24 rare inherited CNVs in 19 familial cases affecting 52 genes (Tables S2 and S3 ). The frequency of carriers of rare inherited structural lesions is Ϸ40% (19 out of 48) in our cohort of familial cases as compared to the Ϸ20% (32 out of 159) collective rate of inherited CNVs among unaffected individuals from the same population (15) (relative enrichment 1.97, Fisher's Exact Test P ϭ 0.01) ( Table 1) . Cases and controls carry on average 0.5 (24 CNVs in 48 cases) and 0.2 (32 in 159 controls) rare CNVs per person, respectively, a Ϸ2-fold difference in rare CNV burden. It should be noted that our population-specific filtering process is preferable to the one based on the diverse set of CNVs present in the database of genomic variants (DGV) (16) because DGV includes samples that have not been screened for psychiatric phenotypes and likely includes several pathogenic variants, and in addition, CNV frequency and diseasepenetrance may vary across human populations (21) . Nevertheless, essentially identical enrichment (relative enrichment 1.85, 27% vs. 14.5%, Fisher's Exact Test P ϭ 0.05) was obtained upon further filtering that removed rare inherited variants overlapping with DGV (hg18 version 4). Familial clustering offers an important validation measure for all identified CNV regions (22) . Nevertheless, we also confirmed, in four out of four tested families, the observed patterns of inheritance using an independent approach, the multiplex ligation-dependent probe amplification (MLPA) assay (23) (see SI Methods and Fig. S2 ).
Two lines of evidence suggest that the observed Ϸ2-fold enrichment of rare inherited CNVs in familial SCZ has a bone fide pathogenic basis. First, the observed enrichment in inherited structural mutations is highly specific, since we did not find any enrichment of de novo structural lesions in the same familial cases cohort (15) . Second, as would be expected for pathogenic lesions, the enrichment in inherited CNVs among familial cases is confined exclusively to CNVs overlapping at least one gene, either partly or in its entirety (herein referred to as genic CNVs). Specifically, when we analyzed CNVs separately according to their gene composition, we found that individuals with familial SCZ were Ϸ2.7 times as likely as controls to harbor rare genic CNVs (relative enrichment 2.7, Fisher's Exact Test P ϭ 10 Ϫ3 , Table 1 ). Essentially identical enrichment in genic CNVs (relative enrichment 2.6, 25% vs. 9.5%, Fisher's Exact Test P ϭ 0.012) was obtained upon further filtering that removed rare inherited variants overlapping with DGV (hg18 version 4). In contrast, there was no significant difference in the proportion of cases versus controls carrying rare nongenic CNVs (Table 1) . Moreover, no such enrichment in inherited genic CNVs was observed in the cohort enriched for sporadic cases (relative enrichment 1.2, P ϭ 0.52), where the contribution of inherited CNVs appears to be relatively minor. In that respect, it is noteworthy that while the overall frequency of carriers of all rare structural variants is the same between the familial and sporadic cases (15) (Ϸ40%), the type of variants is markedly different (Fig. 1A) . Sporadic SCZ is characterized by a marked enrichment of rare de novo mutations and only a modest increase in the rate of rare inherited CNVs, which do not appear to preferentially affect genes. By contrast, familial SCZ is characterized by enrichment in rare inherited genic CNVs (predicted to have higher penetrance), while de novo mutations are less prominent. None of the rare CNVs found in familial cases are present in control chromosomes. To identify which of these CNVs are most likely to be pathogenic, we investigated the relationship between rare inherited CNVs and disease status within each family. For 12 of the 19 CNV carriers, DNA samples and genotypic information were available for at least one more affected relative. In nine of these 12 families, the CNV segregated to all genotyped affected members (only two of the 23 affected members of these nine families were not available for genotyping). Thus, CNVs in these nine families showed clear co-segregation with the clinical diagnosis, in a manner consistent with incomplete penetrance models (i.e., present also in some unaffected family members) (Fig. 1B) . The remaining three CNVs segregated only to one of the genotyped affected members in each family. Given the Ϸ20% basal rate of inherited CNVs in unaffected controls (15) , these are likely to be neutral variants. Alternatively, these cases may be indicative of more complex modes of inheritance, such as bilineal transmission of risk alleles. To exclude that the observed pattern of co-inheritance of CNVs and diagnosis in the informative families is due to chance alone, we conducted a simulation study where we disrupted the relationship between CNVs and diagnosis by permuting the diagnosis, while keeping constant the pedigree structure, the inherited pattern of CNVs Statistical significance was determined using Fisher's exact probability test; NS ϭ non-significant. and the number of affected individuals in each family. Coinheritance of CNVs and diagnosis in nine out of 12 families was observed only once in 10,000 permutation runs (empirical P value ϭ 0.0001) and, therefore, it is unlikely to be due to chance. The nine CNVs segregating to all genotyped affected members within the respective families, alter 12 known genes: PEX13, KIAA1841, AHSA2, USP34, C4orf45, RAPGEF2, PTPRN2, CSMD1, NRG3, MACROD2, A26B3, and LOC441956, all of which are candidates for follow-up studies. Convergence with previous studies highlights at least two of these genes as particularly worthy of follow-up. Specifically, the neuregulin-3 (NRG3) gene is implicated by a 73.6-kb-long duplication in the first intron, which may cause regulatory deficits. An overlapping CNV has been reported previously in one case with SCZ (24) ( Table S2 ). Three SNPs in the same intron were recently associated with SCZ-related quantitative traits (24) . The homologous gene, NRG1, is also a well-known candidate gene (25) . In addition, the RAPGEF2 gene, encoding for a GTP exchange factor, is implicated by a 716.4-kb duplication that encompasses this gene. Mutation of the RAPGEF2 ortholog in mice affects the formation of the cerebral cortex, reduces the threshold for the induction of epileptic seizures and results in commissural fiber defects (26) . Previously, we have identified in a patient with SCZ a de novo exonic microdeletion affecting another member of the RAPGEF family (RAPGEF6) located within a SCZ susceptibility locus at chromosome 5q (15) . Mutations in another member of this family (RAPGEF4) have been described in autism (27) .
We examined the familial cases for differences in clinical and phenotypic variables (history of developmental delays or learning disabilities, mental retardation, age at onset, and disease severity) that may discriminate inherited CN mutation carriers. We focused our analysis on probands from families where CNVs show apparent co-segregation with the illness and are therefore more likely to be pathogenic. Among them, the male to female ratio is identical to that of the entire familial cases cohort, and there is no statistically significant evidence for parental origin effects. None of these probands had a history of developmental delays or learning disabilities, or presence of mental retardation. In addition, there was no difference in the age at disease onset between these probands and noncarriers of rare CNVs, but we found some suggestive differences in indices of disease severity, including co-morbid substance abuse (67% versus 23%, P ϭ 0.03, uncorrected), duration of illness (141.6 months versus 92.2 months, P ϭ 0.19), and number of hospitalizations (4.9 compared to 2.9, P ϭ 0.13), indicating a more debilitating or treatment-resistant form of illness among CNV carriers.
High-Density Linkage Analysis. Previously, a low-density (9-cM) linkage scan in our Afrikaner sample identified suggestive evidence for linkage at 13q34 and 1p36 (maximum nonparametric LOD scores 2.99 and 2.23, respectively) (12). Here we genotyped 2005 di-, tri-, and tetra-nucleotide repeat microsatellite markers, in one of a few linkage scans of psychiatric disorders to attain this level of genome-wide coverage. The average inter-marker distance was 1.9 cM (Ϯ1.4), and the average heterozygosity for the autosomal markers was 0.71 (Ϯ0.12) resulting in an information content of 0.84 (Ϯ0.046) (Figs. S3, S4). We conducted both parametric and nonparametric analyses. For our parametric analyses, we used the algorithm implemented in LAMP to estimate the disease allele frequency and genotype penetrances by maximum likelihood. We used the optimized parameters to calculate model maximized LOD (MOD) scores, which are more powerful than LOD scores when the disease parameters are unknown (28) .
Singlepoint Parametric Results. We found three markers with a MOD score of at least 3.0 in either affection category: D13S285 on 13q34, D9S50 on 9p13, and D21S270 on 21q22. The highest MOD scores for both affection statuses are for D13S285, located at 127 cM. For the narrow affection status the MOD score is 3.30 and for the broad classification is 3.67. D9S50 at 60 cM has a MOD score of 3.56 for the broad classification and 2.51 for the narrow. For D21S270 at 46 cM, the MOD score for the narrow classification is 3.0 and for the broad is 1.88 (Table S4) .
Multipoint Parametric Results. For our multipoint parametric analysis ( Fig. 2) , the maximum MOD scores for both affection classifications are also on 13q34. The maximum MOD score for the narrow affection status is 3.13 at 126 cM. When we repeated the linkage analyses on 1,000 simulated data sets, we calculated an empirical P value of 0.093. For the broad affection status, the highest MOD score is 3.76 at 131 cM, near D13S293, and the 1-MOD region spans from 115 cM to the q terminus. The empirical P value for the broad affection status alone is 0.025. When we include both the narrow and broad classifications in our simulations, 42 of the data sets resulted in a MOD score greater than or equal to 3.76. This empirical genome-wide P value of 0.042 meets the criteria for a significant linkage result (29) . For the broad phenotype, the maximum likelihood estimate for the disease penetrance for an individual with two copies of the disease allele is 1.0, for an individual with one copy is 0.073, and for an individual with no copies is 0.005. Although the disease allele frequency is estimated to be fairly rare (f d ϭ 0.030), the relative risk is very high (RR ϭ 13.77). In addition to the 13q locus, we identified linkage peaks on chromosomes 21q22 at 46 cM, near D21S1900, with a 1-MOD interval from 41 to 48 cM and on 9q21 at 85 cM, near D9S1877, with a 1-MOD interval from 80 to 96 cM (Table 2) .
Singlepoint Nonparametric Results. The highest LOD score is for marker D1S2885 at 46 cM on 1p36. The LOD score for the narrow classification is 2.30, and is the genome-wide maximum at 2.87 for the broad classification. D13S285, at 127 cM on 13q34, has elevated LOD scores for both the narrow and broad classifications; the LOD scores are 2.80 and 2.70, respectively. Also noteworthy are three adjacent markers on 21q22 with LOD scores greater than 2.0 using the narrow category: D21S1900 (LOD ϭ 2.30), D21S1919 (LOD ϭ 2.55), and D21S270 (LOD ϭ 2.31). For the broad category these three markers have LOD scores ranging from 1.20 to 1.53 (Table S5) .
Multipoint Nonparametric Results.
The maximum multipoint LOD score is located about 2 cM away from D13S285 at 125 cM on 'A' is the disease allele, 'a' is the non-disease allele. 1-MOD, region in which the MOD score is within 1 MOD score of the highest MOD score; Aff, affection classification; N, narrowly affected; B, broadly affected; Freq, allele frequency; RR, relative risk based on a 1% prevalence of SCZ; Pen, penetrance of SCZ for the given genotype. Therefore, Pen of AA is the probability of having SCZ, given two copies of the disease allele.
13q34. At this location, the LOD score for the narrow classification is 2.65; for the broad classification the LOD score is slightly higher at 2.66. The 1-LOD interval around this peak extends from 119 cM to the q terminus. However, the empirical significance based on 1,000 simulations is not significant (P ϭ 0.25). The nonparametric multipoint analysis also provides evidence for linkage at 21q22. The LOD scores are 2.16 for the narrow and 0.83 for the broad classification (Table S6 ). This is the region where three markers showed evidence for linkage in the singlepoint analysis.
Targeted Analyses in Families Nonlinked to Chromosome 13. Twentyfive of our families in our sample exhibited a MOD score of Ͻ0.0 at the location of our strongest linkage peak, at 131 cM on chromosome 13q34 near marker D13S293. To examine evidence for additional susceptibility loci, we carried out a series of analysis targeted at these 25 families (Table 3) . Notably, the maximum MOD score in these 25 families occurs on chromosome 1p36 at 35 cM (Ϸ1 cM from D1S2644), near the peak that was identified in our previous 9-cM scan. The MOD score for the narrow classification at that position is 3.21 (empirical P value ϭ 0.15); the MOD score for the broad classification is 1.74. The nonparametric LOD scores in the region (both at Ϸ29 cM, near D1S2697) were only 1.32 and 0.54 for the narrow and broad classifications, respectively. The MOD score analysis results suggest a dominant mode of inheritance, with the estimated disease allele frequency of 0.003 and penetrances/genotype relative risks of 1.0, 0.93, and 0.004.
Exploration of the Relation Between Linkage Signals and CNVs.
We first assessed the contribution of copy number mutations to the two primary and consistent among studies linkage signals at 13q34 and 1p36. Whole genome CNV annotation, conducted using dCHIP program, identified 788 putative CNVs in the 241 cases included in our scan. In the 13q34 region, there was only one CNV identified, which did not overlap with any gene (Table  S7 ). This CNV was found in two out of 224 cases (0.89%) and three out of 361 parents of unaffected controls (0.83%). In the 1p36 region, there were seven CNVs including six genomic gains and one loss (Table S7 ). There was no statistical difference in the frequencies of these CNVs between cases and controls. None of the identified CNVs was present in families linked to the respective linkage loci. Thus, at the level of resolution of our scan, we could not identify any CNV that accounts for the linkage signals identified.
Because only a subset of the families used in the linkage studies (n ϭ 32) were also included in the CNV scan and additional, yet unidentified rare CNV carrying families are likely to be part of the linkage cohort, it is not possible at this point to conclusively evaluate the effect that removal of families, which carry at least one rare CNV, has on linkage. Nevertheless, preliminary analysis shows that, despite the decrease in the sample size, after removing CNV carrying families (n ϭ 14, eight of them with CNVs co-segregating with the clinical diagnosis), the evidence for linkage in 13q34 remained unchanged (MOD ϭ 3.77). To estimate the expected change, under the assumption that the families removed from the analysis are contributing to the 13q34 signal, we randomly removed 14 families from among the ones showing linkage to 13q34. In 100 trials, the MOD scores varied from 0.53 to 2.76 for the narrow definition, with an average of 1.50, and from 0.63 to 2.99 for the broad definition, with an average of 1.74. This notable reduction in the MOD score suggests that at least compared to the families linked to 13q34, the rare CNV containing families may represent a largely distinct subset of genetic liability. Interestingly, our exploratory analysis shows that in a number of loci, weak linkage signals are amplified following removal of rare CNV families despite decrease in power (for example, at 3q21 MOD increases from 1.95 to 2.3 for the narrow classification, at 9p24 MOD increases from 1.68 to 2.13 for the broad classification, and at 16p13 MOD increases from 1.64 to 2.3 for the broad classification). These may reflect true linkage signals, which are masked by the heterogeneity introduced by the rare CNV families.
Discussion
Our results offer a comprehensive picture of the genetic architecture of familial SCZ in a relatively homogeneous population. Our chromosomal variation analysis provides evidence for a role of inherited structural lesions in familial SCZ and highlights some important differences in the genetic architecture of familial and nonfamilial forms of the disease. The majority of the identified inherited CNVs, co-segregate with disease in a manner consistent with necessary but not always sufficient genetic ''hits,'' which lead to a disease state only in combination with additional, inherited structural or sequence variation or environmental factors. Patient stratification suggests that inherited CNVs do not correlate with history of developmental delays, learning disabilities, or presence of mental retardation, but appear to be enriched in more debilitating or treatment-resistant form of illness. Although our study is statistically underpowered to prove the involvement of any specific CNV, analysis of co-segregation with the clinical diagnosis, as well as convergence with previous studies, highlights a number of genes, gene families, and related pathways (such as the contactin family, the CSMD1, ADARB1, RXFP2, LRFN5, and NRG3 genes) as particularly worthy of follow-up (see SI Text). In particular, we provide additional evidence strongly supporting a previously unknown role of a family of Rap1 guanine nucleotide exchange factors (RAPGEF family) and Rap1-mediated processes (30) in psychiatric disorders.
Our linkage analyses indicated one or more genes that increases susceptibility to SCZ on chromosome 13q34 in our broadly affected individuals. It is noteworthy that three of the four other SCZ linkage scans that identified a LOD score greater than 2.0 at 13q34 included schizoaffective disorder, bipolar type in the affection category (7-10). That our broad classification also includes this diagnosis supports the hypothesis that one or more genes on 13q34 increases susceptibility to SCZ and bipolar spectrum disorders. Based on the results of this study and previous ones, there is considerable evidence for linkage to 13q. When we analyzed families that do not show evidence for linkage to 13q34, we identified another linkage peak on 1p36. This result was much stronger when we used the narrow definition of SCZ that did not include schizoaffective disorder, bipolar subtype. Compared to the 13q34 locus, this could indicate different causal alleles and mechanisms in subjects with and without symptoms of bipolar disorder. Notably, at the level of resolution of our scan, our analysis indicates that CNVs within both linkage signal regions are likely to be neutral and unlikely to account for the linkage signals identified. Finally, although the sample sizes are relatively small, our findings suggest that compared to the families linked to 13q34, the rare CNV carrying families represent a largely distinct subset of genetic liability. CNV carrying families may be a source of heterogeneity and future studies will focus on identifying all rare CNVs as putative risk loci and as a tool to stratify the samples to reduce genetic heterogeneity for linkage analyses and improve detection of weak signals.
Irrespective of the pathogenic potential and the precise mode of action of each risk locus, our results highlight the difference in the genetic architecture of the familial and sporadic forms of the disease and support the notion that multiple genetic variants, including individually rare ones (often unique to a single patient) that affect many different genes contribute to the genetic risk of familial SCZ. This heterogeneity (present to some degree even in founder populations) is consistent with the hypothesis that there are many genes that contribute to SCZ and may account for past and present difficulties in finding bone fide genetic variants. Because there are significant clinical similarities of SCZ cases diagnosed in Afrikaners and those diagnosed in more heterogeneous populations (such as the U.S.) (20) , our results are likely to have general implications regarding the genetic architecture of SCZ.
Samples and Methods
Cohorts. Both affected and control families were recruited and diagnosed as part of our ongoing, large-scale genetic study of SCZ in the Afrikaner population in South Africa, as previously described (12, 15, 20) (see also SI Methods). For our linkage study, affected subjects were classified as either narrowly or broadly affected. The narrow diagnosis includes subjects with SCZ or schizoaffective disorder-depressive type, as previously described (12) . The broad diagnosis includes all individuals classified as affected under the narrow definition as well as individuals with schizoaffective disorder-bipolar type. Compared to our previous classification (12) , it is more encompassing than LCI, but not as broad as LCII. For our CNV studies, the criteria for inclusion in the affected cohort are: (i) Afrikaner heritage; (ii) proband meeting full diagnostic criteria for SCZ or schizoaffective disorder; and (iii) both biological parents alive and willing to participate. It should be noted that presence of negative or positive family history or availability of additional affected relatives is not a screening criterion. Nevertheless, for all recruited subjects, detailed information about family history of any psychiatric or medical illness was solicited from at least three sources (proband and each participating parent) by two independent raters [the nursing sister, who completes the Medical and Personal History form with each study participant and also draws a detailed pedigree for at least three to four generations for each family, as well as the psychiatrist who administers the Diagnostic Instrument for Genetic Studies (DIGS) to the proband]. In addition, since we also trace the ancestry of all recruited families, we routinely use several informants in each family to inquire about all relatives' names, date and place of birth, and death and psychiatric status. Because of the close-knit family structure of the Afrikaner families and the availability of detailed psychiatric records over several generations due to the large catchment area and long-term care provided by the local recruiting hospital, we are typically able to obtain information about psychiatric status for at least three to four generations removed from the proband. For any relative identified as possibly having symptoms of SCZ or schizoaffective disorder, or a history of treatment or hospitalization for a psychiatric condition, every effort was made to include that relative in the study, if alive and willing to participate, by obtaining a blood sample and administering an in-person diagnostic interview. In a few instances where the exact nature of a reported psychiatric diagnosis in a first-or second-degree relative could not be substantiated (i.e., because the person was not alive or access to records was not possible), the family history status was left unknown. Such families are not considered in the present study or in the Xu et al. study (15) . Finally, in addition to being matched by ancestry, a subset of the control families (three informants per family inquiring for up to three generations) completed a detailed self-report questionnaire that inquired about several psychiatric conditions, including psychosis, phobias, anxiety, and depression (see also SI Methods).
Genotyping procedures, linkage analysis and CNV identification, and verification are outlined in detail in the SI Methods. Table S3 have not been directly associated with schizophrenia (SCZ) in the literature, some of them have been implicated in psychiatric and other neurobehavioral disorders or in mechanisms that may underlie predisposition to such disorders. Two examples (NRG3 and RAPGEF2) are discussed in the main text, but a few additional examples are provided below:
The Contactin Family. Burbach and van der Zwaag (1) recently provided a detailed account of the contactin system and its potential contribution to a number of different psychiatric and neurobehavioral disorders, including SCZ and autism. In an early study, Fernandez et al. (2, 3) showed that disruption of contactin 4 (CNTN4) results in developmental delay and other features of the 3p deletion syndrome. In the present study, we identified a CNV at Ϸ130 kb downstream of CNTN6 (also named NB3), another member of the contactin protein family. Interestingly, in an independent study, we identified another CNV disrupting the contactin associated protein 2 (CNTNAP2) that co-segregates with psychosis in one family. Structural variants in the CNTNAP2 gene have been reported in patients with psychosis in at least two previous genome-wide scans (4, 5). Thus, our results support the notion that abnormalities in the contactin family proteins may be involved in SCZ and other psychiatric conditions.
The CSMD1 (CUB and Sushi Multiple Domains 1) Gene. One CNV identified in the present study is a duplication at 8p23.1-8p23.2 involving the CSMD1 gene. A recent study (6) showed that a transmitted duplication at 8p23.1-8p23.2 affecting the CSMD1 gene may be associated with speech delay, autism, and learning difficulties.
The ADARB1 (adenosine deaminase, RNA-specific, B1) gene: ADARB1 (also named ADAR2) encodes for adenosine deaminase, a key RNA editing enzyme. Although ADARB1 has not been directly associated with psychiatric conditions, mRNAs for several important neuronal receptors such as 5-HT2CR and GLUR2 undergo posttranscriptional editing. Abnormal editing of HT2CR has been implicated in depression and SCZ (7) .
Other potentially interesting genes include the RXFP2 (relaxin/insulin-like family peptide receptor 2) gene (also known as LGR8), a member of the relaxin family peptide receptor system whose members are distributed in both excitatory and inhibitory neurons in the brain and modulate diverse behaviors (8) , as well as the LRFN5 (leucine-rich repeat and fibronectin type III domain containing 5) gene (also named SALM5), which is expressed exclusively in neuronal tissues, especially in mature neurons. Several members of the LRFN protein family were shown to associate with PSD-95 (9, 10).
SI Methods Patient Cohorts.
We performed a genome-wide survey of rare inherited CNVs in a total of 182 individuals, consisting of 48 probands with familial SCZ (positive disease history in a firstdegree (n ϭ 33) or second-degree (n ϭ 15) relative and both of their biological parents, as well as all additional affected relatives that were available for genotyping. Of the 33 families with a history of SCZ in a first-degree relative, 17 are parent-child pairs, 12 are sibling pairs, and four families are both. In eight of these 33 families, in addition to the first-degree relative, there is at least one second-degree relative who is also affected with SCZ (Fig. S1 ). Of the 15 families with a history of SCZ in a second-degree relative, 11 are avuncular pairs, three are grandparent-grandchild pairs, and one family is both. For our linkage studies, we genotyped 479 subjects from 130 families. Sixty-nine families are informative. In the 54 informative families with at least two affected members, there are 60 and 79 affected relative pairs for the narrow and broad affection categories, respectively. Of the broadly affected relative pairs, 30 are sibling, 24 are parent-child, 14 are avuncular, six are cousin, three are second cousin, and two are grandparent-grandchild.
All subjects were confirmed as Afrikaners by tracing ancestry back to the 1800s using state and church records and finally to the initial 2,000 founders through the Genealogies of Old South African Families. Diagnostic evaluations were conducted inperson by specially trained clinicians using the DIGS, which was translated and back-translated into Afrikaans. Upon completion of the DIGS, the interviewers assigned DSM-IV diagnoses and completed a detailed narrative report. All narratives and DIGS were independently evaluated by appropriately trained clinicians in New York.
Sample Characteristics. The familial cases sample consisted of 31 males (65%) and 17 females (35%) and both their biological parents. The sample enriched in sporadic cases consisted of 108 males (71%) and 44 females (29%) and both their unaffected biological parents. The control sample consisted of 93 females (58%) and 66 males (42%) and both their biological parents. It should be noted that both in this study and our previous Xu et al. (11) study we did not find any sex-specific differences in distribution of CNVs. We checked for population stratification between cases and controls using principal component analysis as implemented in EIGENSTRAT (12) . Both groups overlap in the graphical representation of the top two principal components (eigenvectors), indicating no evidence of stratification.
The phenotypic variables analyzed in the CNV scan, were defined as follows: History of developmental delay was recorded as positive when there was clear history of maturation lag or milestone delays before the age of 6 (i.e., delayed crawling, walking, speaking, etc.). History of learning disabilities was recorded as positive if there had been a diagnosis of a learning disability, or clear history of being a ''slow learner,'' requiring remediation at school, or placement in a special class. Age at onset was defined as the age at which full DSM criteria for schizophrenia or schizoaffective disorder were met.
Genotyping. For the linkage analysis, genotyping for 2005 di-, tri-, and tetra-nucleotide repeat microsatellite markers was performed by deCODE (Reykjavik, Iceland), through their fee-forservice genotyping facility. Among them, 1,904 autosomal markers and 76 chromosome X markers passed our internal quality checks. Of the 960,395 possible genotypes, 878,046 were successfully called, corresponding to an average (ϮSD) per marker genotyping rate of 91% (Ϯ7%).
For the CNV analysis, the families were genotyped using Human Genome-Wide SNP Array 5.0 (Affymetrix), which contains 500,568 SNPs, as well as 420,000 additional nonpolymorphic probes that can assess other genetic differences, such as CN variation. Samples were processed as previously described (11) . Average call rate on arrays used in this study was 99.43%. All microarray experiments were performed in the Vanderbilt Microarray Shared Resource directed by Dr. Shawn Levy.
CNV Identification, Inherited CNV Detection, and Inherited CNV Verification. CEL files from all chips were analyzed using two software packages, DNA-Chip Analyzer (dChip) and Partek Genomics Suite (Partek software, version 6.3 Beta, build #6.07.1127; Partek), as previously described (11) . The entire procedure included five steps: (i) quality control; (ii) CNV identification; (iii) inherited CNV detection; (iv) inherited CNV verification by intensity and genotyping filters; and (v) inherited CNV confirmation by MLPA.
(i) Quality control: A quality control step was conducted to exclude families with one or more hybridization failures.
(ii) CNV identification: All CEL files that passed the quality control step were imported and analyzed by dCHIP (13) (14) (15) and Partek according to the authors' instructions. For the dCHIP analysis, data were processed in batches, each batch containing arrays processed simultaneously in 96-well plate formats. An array with median overall intensity within each batch was chosen as the baseline to adjust the brightness of all arrays to a comparable level. Arrays were then normalized at probe intensity level using the Invariant Set Normalization procedure (14) . Following normalization, a CNV identification step ensued. A reference signal value was first calculated for each probe set using a model-based method. To obtain reference signal distribution (blind to the affected status information), we assumed that for any locus, less than 10% of all of the samples show abnormal CN. Thus for a given probe set, 5% of samples with extreme signals were trimmed from each end, and the rest of the values were used to estimate the mean and standard deviation of the signal distribution of normal CN (n ϭ 2). For probe sets located on the X chromosome, a ''Gender'' information file was used so that signal from male subjects was considered as one copy and signal from female subjects as two copies when computing mean signal intensity. Two pseudoautosomal regions (PARs) on chromosome X defined by Affymetrix annotation files [GenomeWideSNP5 Annotations, CSV format (11/28/07)] were excluded from our analysis. The observed raw CN was then defined based on the reference signal for each probe set of each sample and a ''Hidden Markov Model'' (HMM) algorithm was used to infer CN and identify CNV regions. In determining CN, we also used the median smoothing method implemented in the dCHIP package. Compared to the HMM method, median smoothing has the advantage of providing results close to the raw CN but robust to outliers, and it does not require the stringent parameter specification required in HMM fitting. We used the CN inferred by this method for the inherited CNV confirmation step (see below). To reduce the false positive rate, we excluded the triads that have one or more individuals with more than 35 CNVs per chip for all follow-up analysis, as suggested in Szatmari et al. (15) .
The Partek Genomics Suite (version 6.3 Beta, build #6.07.1127) uses both the SNP and nonpolymorphic CN probe sets on Affymetrix GWS 5.0 chip. During the data importation stage, all raw signal intensities were adjusted for fragment length and probe sequence, and quantile-normalized to generate normalized signal intensities for all genomic markers on the arrays. To identify CNVs, we used a reference sample set consisting of all unaffected mothers. Normalization was first performed on the reference sample set; the experimental samples were then normalized to the same distribution as the reference samples. A CN baseline created from the Reference set was used for CNV identification. The resulting data were scanned for regions of genomic gain or loss, with a minimum region size of three probe sets using a HMM algorithm. For every male sample, losses with a CN of 0, and gains with a CN of 2 for any X chromosome region were extracted.
CNV regions for each sample identified by the two software packages were then merged into a single list of nonredundant CNVs. CNVs were combined if they overlapped by 50% or more in length. The borders listed are the outermost borders defined by either analysis.
(iii) Rare inherited CNV detection: The CNV list generated above was first divided into two lists, a deletion list (mean CN Ͻ 1.25 for autosomal or mean CN Ͻ 0.25 for chromosome X) and a duplication list (mean CN Ͼ 2.75 for autosomal or mean CN Ͼ 1.75 for chromosome X). Deletion and duplication analyses were conducted separately. A candidate inherited CNV was considered for further analysis only if there was more than 50% overlap in size with a variant at the same locus in the biological parental chromosomes (size of overlap/total size of merged CNVs Ͼ 0.5), but less than 50% overlap in size with any variant in the other parental chromosomes.
(iv) Inherited CNV verification using genotype information and median smoothing inferred CN: The vast majority of CNVs are inherited from parents (16) and since the false-positive or false-negative prediction rate is relatively high in all available CNV detection algorithms (17) , it is important to use independent CNV inferring methods, as well as family information for validation of inherited CNV calling results. Genotyping calls and Median smoothing inferred CN calls for all samples were stored in MySQL database (version 5.1) along with the related pedigree information. For each identified candidate CNV, all genotypes and inferred CN of SNPs within the region were retrieved for each triad (the subject and his/her parents). Loss of heterozygosity (LOH), Mendelian inconsistencies and average median smoothing inferred CN of the region were analyzed in Microsoft Excel driven by a VBA script and further examined visually. A number of rules were applied to determine whether a candidate CNV in a child is a true inherited CNV:
1. Average inferred CN: Average inferred CN of the normal parent should be close to two for an autosomal region. The average inferred CN of the child and the mutation-carrying parent should be at least 20% greater (for duplication) or less (for deletion) than the normal parent.
2. Homozygosity/LOH: If a stretch of homozygosity was observed within a candidate deletion CNV, the latter was considered to be a true positive call. Moreover, observation of the same homozygosity in a child and mutation-carrying parent while the normal parent maintains proper heterozygosity was considered a strong indication of an inherited CNV.
3. Mendelian inconsistencies: Presence of Mendelian inconsistencies between the genotype of a child and the normal parent was considered a good indicator of the existence of an inherited CNV in the child.
All rules 1 through 3 were used to provide parental origin information.
(v) Inherited CNV confirmation by MLPA: We independently confirmed the in silico verified CNVs in a subset of families (see main text) using the MLPA approach. Two to three pairs of MLPA target-probes were designed based on the unique sequences within each CNV region. Additionally, three pairs of MLPA control probes from the unique sequences of the VGEFA locus were included in each MLPA reaction. All probes were synthetic oligonucleotides. MLPA reagents were prepared according to the instructions at http://www.mlpa.com/pages/ supportpagepag.html. Final PCR products were analyzed on an ABI3730XL for peak identification and quantification. The peak profiles of all test samples were visualized as shown in Fig. S2 , and parameters (height and area) were extracted using Peak Scanner Software v1.0 (Applied Biosystems). For copy number quantification, the peak areas and heights were exported to a Microsoft Excel worksheet. Peak area and height for each probe was normalized to the mean value for all control probes. The relative ratio of each peak was calculated by comparisons between proband sample and the samples of his/her relatives. Deletion was identified as relative ratio Ͻ0.8 and duplication as relative ratio Ͼ1.2.
Simulation Test. An excel VBA script was used to drive the randomization of the phenotypes within each family and the simulation process. For all of the pedigrees used, the pedigree structure, CNV inheritance pattern, and number of affected individuals were kept constant. For the individuals within a pedigree with known phenotype but no genotype (CNV) information, the program randomly assigned a CNV with a probability of 0.25 (the chance that a CNV is inherited from a heterozygous parent). The pattern of co-inheritance of CNVs and diagnosis within each family was determined based on two rules: (i) two or more affected individuals carry the CNV in the given family and (ii) all of the affected individuals in the family carry the CNV. When these two conditions were satisfied, the family was scored as showing co-segregation of CNV and clinical diagnosis. To estimate the empirical P value, we ran the simulation 10,000 times.
Linkage Analysis. DNA from all study participants was extracted from 24 mL EDTA-treated blood, according to standard procedures (18) . The deCODE genotyping protocol involves PCR amplification followed by capillary electrophoresis and automated allele calling by deCODE's Allele Caller software. Among all of the markers genotyped, 1,904 autosomal markers and 76 chromosome X markers passed our internal quality checks, which are described in detail below.
Error Checking. Before linkage analysis, we verified reported relationships using genetic marker data. To do this, we used GRR to examine identity-by-state distributions for all pairs of individuals (19) (Fig. S3) . We identified three instances of nonpaternity and one set of individuals who appeared to be switched. Using the X chromosome information, we identified one subject who had the appropriate levels of identity-by-state with their relatives, but was labeled as a male while appearing to be genetically female. The pedigree file was corrected to resolve these discrepancies.
Additionally, we identified problematic markers that either exhibited more than four Mendelian errors or in a subset of 210 unrelated subjects, deviated from Hardy-Weinberg equilibrium (HWE) at P Ͻ 0.01. These tests help identify markers with high rates of genotyping error (20) . We excluded 12 markers with more than four Mendelian errors and another 12 markers with evidence for deviations from HWE. Thus, among the 2,005 genotyped microsatellites, 1,981 (99%) passed these initial quality filters. The error checks were conducted using Pedstats (21).
Genetic Map Validation. All of our multipoint analyses are based on the deCODE linkage map (22) . For markers that did not have unique positions, we adjusted cM positions slightly according to the UniSTS National Center for Biotechnology Information (NCBI) database (www.ncbi.nlm.nih.gov). This small adjustment avoided problems with likelihood calculations when obligate recombinants are encountered in intervals of length zero. Since the results of multipoint linkage analysis can be sensitive to errors in genetic maps, we checked the agreement of our genotyped data and the published map by comparing the likelihood of the entire genotype set when: (i) all markers were analyzed in their original locations; (ii) the order of two consecutive markers was switched; and (iii) the position of a specific marker was changed so that it was unlinked to all others (this analysis should identify markers that are mismapped, perhaps due to an error in tracking primers during genotyping). By performing these checks, we identified one marker that appeared to be at the incorrect location on the chromosome (D14S56) (difference in likelihood is 116.3; average Ϯ SD likelihood difference for all other markers is Ϫ14.12 Ϯ 16.17). This marker was not included in subsequent analyses, resulting in a total of 1,980 analyzed markers.
MOD Score Parametric Linkage Analysis. Since the mode of inheritance for SCZ is unknown, we performed multipoint parametric MOD score linkage analysis using LAMP (23, 24) , calculating the MOD scores at 1-cM intervals along the autosomes. In contrast to conventional parametric linkage analysis, MOD score analysis does not require the disease allele frequency and penetrance parameters to be specified a priori; they are estimated at each location using maximum likelihood. Thus, we expect MOD score analysis to be more powerful than both traditional parametric and nonparametric analysis in situations where the mode of inheritance is uncertain. We initially used the unconstrained (free) model, however since most of our families include a single affected relative pair, we used a multiplicative model that required estimation of only two parameters (disease allele frequency and effect size). We report the multiplicative results unless otherwise specified.
Nonparametric Linkage Analysis. We also tested for linkage to a SCZ locus with multipoint and singlepoint nonparametric linkage using the S all statistic (25) . Both multipoint and singlepoint analyses were performed, because multipoint analysis is more powerful, while singlepoint analysis may be more robust to genotyping errors (26) (27) (28) . The S all statistic tests for excess identity-by-descent allele sharing between all pairs of affected individuals within a family. We used the excess-sharing parameterization modified statistic (29) as implemented in Merlin (30) . LOD scores were calculated at 1-cM intervals across all chromosomes. To evaluate evidence for parent-of-origin effects, we defined a nonparametric linkage statistic (25, 31) that measured allele sharing for maternally inherited alleles only. In each case, these statistics considered all pairs of affected individuals in each pedigree. For each inheritance vector, each pair was scored according to whether they shared their maternally inherited allele [1] or not [0] . An overall nonparametric statistic was calculated for each pedigree by summing all pair specific statistics and converted to a LOD score as previously described (25, 31 ). An analogous statistic was defined to evaluate sharing of paternally inherited alleles.
Empirical Significance Levels. To assess the significance of our results, we simulated genotypes for 1,000 data sets by gene dropping as implemented in Merlin. The data sets used the same family structures, included the same 1,980 markers and both phenotypes. To determine an empirical distribution of maximum genome-wide MOD (or LOD) scores, we repeated our analysis using the simulated data sets. We then counted the number of times a simulated dataset resulted in a genome-wide maximum MOD (or LOD) score greater than or equal to our experimental genome-wide maximum MOD (or LOD) score. To obtain our empirical P value, we divided this count by the number of simulations performed.
Detection of Copy Number Mutations at the Linkage Loci.
To assess the contribution of copy number mutations to the linkage signal in the Afrikaner families, a whole genome CNVs annotation was conducted using dCHIP program, in all 241 cases included in our scan as well as in the 361 parents of our unaffected controls (control sample). The quality control and CNV identification steps were similar to the description for rare inherited CNV detection steps except all CNVs in cases and controls (224 and 361, respectively) were not filtered through the criteria used to identify rare CNVs. Following the CNV identification step, all CNVs within the cytoband corresponding to the linkage peak region were extracted. A copy number region (CNR) was identified if two or more CNVs overlapped 50% in length. All CNVs within a CNR were then separated according to diagnosis and the frequencies in cases and control were calculated. S2 . Confirmation of the in silico verified CNVs in a subset of families using the MLPA approach. MLPA analysis confirms that the respective families segregate a duplication on chromosome 2p15, a deletion on chromosome 14q21.1, a duplication on chromosome 4q32.1 and a duplication on chromosome 10q23.1. For each individual in each pedigree, MLPA assay examines three genomic fragments within a control gene (VEGFA) (first three peaks along the x-axis) and two or three genomic fragments within the target CNV region (the rest of the peaks). Within each family, the MLPA tracing of an unaffected individual was used as reference (black tracing). Red tracings in other tracing graphs show a shifted overlaying of the corresponding individual's tracing compared to the reference tracing. When the relative copy number (the peak height) of the control genes is the same between the individual and the reference, the relative copy number of the target region of the individual can be significantly lower than that of the reference (indicative of a genomic loss) or significantly higher than that of the reference (indicative of a genomic gain). Table S3 . Genes located within the inherited CN changes identified in familial cases 
